Advertisement

Effects of coenzyme Q10 supplementation on matrix metalloproteinases and DAS-28 in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial

  • Seyed Mostafa Nachvak
  • Beitollah Alipour
  • Aida Malek Mahdavi
  • Mir Amir Aghdashi
  • Hadi AbdollahzadEmail author
  • Yahya Pasdar
  • Mehnoosh Samadi
  • Roghayeh Mostafai
Original Article

Abstract

Objectives

This study aimed to assess the effect of CoQ10 supplementation on serum matrix metalloproteinases (MMPs) and clinical parameters in rheumatoid arthritis (RA) patients.

Method

In this randomized, double-blind, placebo-controlled trial, 54 RA patients who fulfilled the eligibility criteria (18–56 years, diagnosed at least 6 months ago, with DAS-28 > 3.2) were randomly assigned into two groups to receive 100 mg/day CoQ10 (n = 27) or placebo (n = 27) for 2 months. Serum MMP-1 and MMP-3 levels and clinical status using disease activity score in 28 joints (DAS-28) were assessed before and after supplementation. Data were analyzed using χ2, independent sample t test, paired t test, Wilcoxon, Mann-Whitney, and analysis of covariance.

Results

A significant reduction was observed in both CoQ10 and placebo groups in the medians of serum MMP-1 (0.2 to 0.16, P < 0.001), (0.18 to 0.15, P = 0.001); swollen joint count (2 to 0, P < 0.001), (2 to 0, P = 0.009); and the means of DAS-28 (5.01 ± 1.21 to 2.34 ± 0.68, P < 0.001), (4.88 ± 0.96 to 4.04 ± 1.36, P = 0.009) respectively. Serum MMP-3 level increased significantly in placebo group (2.26 to 2.57, P = 0.020), and the MMP-3 changes between groups were significant (P = 0.027). Furthermore, significant reductions were only observed in ESR, pain score, and tender joint count in CoQ10 group compared with baseline (P = 0.001, P < 0.001, and P < 0.001, respectively). Significant differences were observed between two groups in DAS-28, pain score, and swollen and tender joint count after the intervention (P < 0.001, P < 0.001, and P = 0.012 and P < 0.001, respectively).

Conclusions

It seems that CoQ10 may provide a new complementary approach for RA patients.

Key Points

• CoQ10 supplementation in RA patients attenuated serum MMP-3 level.

• CoQ10 supplementation in RA patients improved clinical outcomes and ameliorated disease severity.

• CoQ10 may provide a new complementary approach for patients with RA.

Keywords

Clinical parameters Clinical trial Coenzyme Q10 Matrix metalloproteinases Rheumatoid arthritis 

Abbreviations

ANCOVA

Analysis of covariance

BMI

Body mass index

CoQ10

Coenzyme Q10

DAS-28

Disease activity score-28 joints

DMARDs

Disease-modifying anti-rheumatic drugs

ESR

Erythrocyte sedimentation rate

FIQ

Fibromyalgia Impact Questionnaire

hs-CRP

High-sensitivity C-reactive protein

IL-1β

Interleukine-1β

IL-6

Interleukine-6

MDA

Malondialdehyde

MMPs

Matrix metalloproteinases

MTX

Methotrexate

TNF-α

Tumor necrosis factor-alpha

VAS

visual analogue scale

Notes

Acknowledgments

We thank all patients for their participation in this study.

Funding information

The research project had a grant from Research Vice Chancellor of Tabriz University of Medical Sciences. The authors thank the Research Vice Chancellor of Tabriz University of Medical Sciences for financial supports.

Compliance with ethical standards

Disclosures

None.

References

  1. 1.
    Aletaha D, Neogi T, Silman A, Funovits J, Felson D, Bingham C, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581CrossRefGoogle Scholar
  2. 2.
    Gabriel SE, Michaud K (2009) Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 11:229CrossRefGoogle Scholar
  3. 3.
    Oliver JE, Silman AJ (2009) Why are women predisposed to autoimmune rheumatic diseases? Arthritis Res Ther 11:252–260CrossRefGoogle Scholar
  4. 4.
    Brennan F, McInnes I (2008) Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 118:3537–3545CrossRefGoogle Scholar
  5. 5.
    Széles L, Töröcsik D, Nagy L (2007) PPAR gamma in immunity and inflammation: cell types and diseases. Biochim Biophys Acta 1771:1014–1030CrossRefGoogle Scholar
  6. 6.
    Ainola M, Mandelin J, Liljeström MP, Li T, Hukkanen M, Konttinen Y (2005) Pannus invasion and cartilage degradation in rheumatoid arthritis: involvement of MMP-3 and interleukin-1b. Clin Exp Rheumatol 23:644–650Google Scholar
  7. 7.
    Tchetverikov I, Ronday H, Van El B, Kiers G, Verzijl N, TeKoppele J, Huizinga TW, DeGroot J, Hanemaaijer R (2004) MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Ann Rheum Dis 63:881–883CrossRefGoogle Scholar
  8. 8.
    Mamehara A, Sugimoto T, Sugiyama D, Morinobu S, Tsuji G, Kawano S, Morinobu A, Kumagai S (2010) Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatic drugs. Kobe J Med Sci 56:E98–E107Google Scholar
  9. 9.
    Sekhon BS (2010) Matrix metalloproteinases an overview. Res Rep Biol 1:1–20Google Scholar
  10. 10.
    Wood AJJ, O’Dell JR (2004) Therapeutic strategies for rheumatoid arthritis. N Engl J Med 350:2591–2602CrossRefGoogle Scholar
  11. 11.
    Crane FL (2001) Biochemical functions of coenzyme Q10. J Am Coll Nutr 20:591–598CrossRefGoogle Scholar
  12. 12.
    Sohet FM, Neyrinck AM, Pachikian BD, de Backer FC, Bindels LB, Niklowitz P, Menke T, Cani PD, Delzenne NM (2009) Coenzyme Q10 supplementation lowers hepatic oxidative stress and inflammation associated with diet-induced obesity in mice. Biochem Pharmacol 78:1391–1400CrossRefGoogle Scholar
  13. 13.
    Carmona MC, Lefebvre P, Lefebvre B, Galinier A, Benani A, Jeanson Y, Louche K, Flajollet S, Ktorza A, Dacquet C, Pénicaud L, Casteilla L (2009) Coadministration of coenzyme Q prevents rosiglitazone-induced adipogenesis in ob/ob mice. Int J Obes 33:204–211CrossRefGoogle Scholar
  14. 14.
    Schmelzer C, Lindner I, Rimbach G, Niklowitz P, Menke T, Döring F (2008) Functions of coenzyme Q10 in inflammation and gene expression. Biofactors 32:179–183CrossRefGoogle Scholar
  15. 15.
    Bessler H, Bergman M, Blumberger N, Djaldetti M, Salman H (2010) Coenzyme Q10 decreases TNF-a and IL-2 secretion by human peripheral blood mononuclear cells. J Nutr Sci Vitaminol 56:77–81CrossRefGoogle Scholar
  16. 16.
    Wang XL, Rainwater DL, Mahaney MC, Stocker R (2004) Cosupplementation with vitamin E and coenzyme Q10 reduces circulating markers of inflammation in baboons. Am J Clin Nutr 80:649–655CrossRefGoogle Scholar
  17. 17.
    Tawfik MK (2015) Combination of coenzyme Q10 with methotrexate suppresses Freund’s complete adjuvant-induced synovial inflammation with reduced hepatotoxicity in rats: effect on oxidative stress and inflammation. Int J Immunopharmacol 24:80–87CrossRefGoogle Scholar
  18. 18.
    Bauerova K, Paulovicova E, Mihalova D, Drafi F, Strosova M, Mascia C, Biasi F, Rovensky J, Kucharska J, Gvozdjakova A, Ponist S (2010) Combined methotrexate and coenzyme Q10 therapy in adjuvant-induced arthritis evaluated using parameters of inflammation and oxidative stress. Acta Biochim Pol 57:347–354CrossRefGoogle Scholar
  19. 19.
    Gvozdjáková A, Kucharská J, Poništ S, Bauerová K (2007) Coenzyme Q10 supplementation in an experimental model of adjuvant arthritis. Fifth Conference of the International Coenzyme Q10 Association, Kobe, Japan Abstract book, JP-053:180–181Google Scholar
  20. 20.
    Spindler M, Beal MF, Henchcliffe C (2009) Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatr Dis Treat 5:597Google Scholar
  21. 21.
    Lee BJ, Huang YC, Chen SJ, Lin PT (2012) Effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease. Nutrition 28:767–772CrossRefGoogle Scholar
  22. 22.
    Cordero MD, Alcocer-Gómez E, de Miguel M, Culic O, Carrión AM, Alvarez-Suarez JM, Bullón P, Battino M, Fernández-Rodríguez A, Sánchez-Alcazar JA (2013) Can coenzyme Q10 improve clinical and molecular parameters in fibromyalgia? Antioxid Redox Signal 19:1356–1361CrossRefGoogle Scholar
  23. 23.
    Cordero MD, Cotán D, del-Pozo-Martín Y, Carrión AM, de Miguel M, Bullón P, Sánchez-Alcazar JA (2012) Oral coenzyme Q10 supplementation improves clinical symptoms and recovers pathologic alterations in blood mononuclear cells in a fibromyalgia patient. Nutrition 28:1200–1203CrossRefGoogle Scholar
  24. 24.
    Reneses S, Pestana L, Garcia A (2012) Comparison of the 1987 ACR criteria and the 2010 ACR/EULAR criteria in an inception cohort of patients with recent-onset inflammatory polyarthritis. Clin Exp Rheumatol 30:417–420Google Scholar
  25. 25.
    Abdollahzad H, Aghdashi MA, Asghari Jafarabadi M, Alipour B (2015) Effects of coenzyme Q10 supplementation on inflammatory cytokines (TNF-a, IL-6) and oxidative stress in rheumatoid arthritis patients: a randomized controlled trial. Arch Med Res 46:527–533CrossRefGoogle Scholar
  26. 26.
    Saghaei M (2004) Random allocation software for parallel group randomized trials. BMC Med Res Methodol 4:1–6CrossRefGoogle Scholar
  27. 27.
    Hammond KA, Litchford MD (2012) Clinical: inflammation, physical, and functional assessment. In: Mahan LK, Escott-Stump S (eds) Krause’s food & nutrition therapy, 13th edn. Saunders, Philadelphia, pp 163–177Google Scholar
  28. 28.
    Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F, Veys EM, Mielants H, Clerck LD, Peretz A, Malaise M, Verbruggen L, Vastesaeger N, Geldhof A, Boullart L, De Keyser F (2005) DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. Arthritis Res Ther 7:R1063–R1071CrossRefGoogle Scholar
  29. 29.
    Sokka T (2005) Assessment of pain in rheumatic diseases. Clin Exp Rheumatol 23:S77–S84Google Scholar
  30. 30.
    Hawker GA, Mian S, Kendzerska T, French M (2011) Measures of adult pain: visual analog scale for pain (vas pain), numeric rating scale for pain (nrs pain), mcgill pain questionnaire (mpq), short form mcgill pain questionnaire (sf mpq), chronic pain grade scale (cpgs), short form 36 bodily pain scale (sf 36 bps), and measure of intermittent and constant osteoarthritis pain (icoap). Arthritis Care Res 63:S240–SS52CrossRefGoogle Scholar
  31. 31.
    DAS 28 calculator V1.1-beta by Alfons and Michiel. Available online: http://www.umcn.nl.DAS28. Accessed on 5 March 2016
  32. 32.
    Nielung L, Christensen R, Danneskiold-Samsøe B, Bliddal H, Holm CC, Ellegaard K, Slott Jensen H, Bartels EM (2015) Validity and agreement between the 28-joint disease activity score based on C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. Arthritis 2015:1–6CrossRefGoogle Scholar
  33. 33.
    Fransen J, Stucki G, Van Riel PL (2003) Rheumatoid arthritis measures: disease activity score (DAS), disease activity score 28 (DAS28), rapid assessment of disease activity in rheumatology (RADAR), and rheumatoid arthritis disease activity index (RADAI). Arthritis Care Res 49:S214–SS24CrossRefGoogle Scholar
  34. 34.
    Abdollahzad H, Alipour B, Aghdashi MA, Asghari Jafarabadi M (2015) Coenzyme Q10 supplementation in patients with rheumatoid arthritis: are there any effects on cardiovascular risk factors? Euro J Integ Med 7:534–539CrossRefGoogle Scholar
  35. 35.
    Lee J, Hong YS, Jeong JH, Yang EJ, Jhun JY, Park MK, Jung YO, Min JK, Kim HY, Park SH, Cho ML (2013) Coenzyme Q10 ameliorates pain and cartilage degradation in a rat model of osteoarthritis by regulating nitric oxide and inflammatory cytokines. PLoS One 8:e69362CrossRefGoogle Scholar
  36. 36.
    Zhang M, Dang L, Guo F, Wang X, Zhao W, Zhao R (2012) Coenzyme Q10 enhances dermal elastin expression, inhibits IL 1 production and melanin synthesis in vitro. Int J Cosmet Sci 34:273–279CrossRefGoogle Scholar
  37. 37.
    Inui M, Ooe M, Fujii K, Matsunaka H, Yoshida M, Ichihashi M (2008) Mechanisms of inhibitory effects of CoQ10 on UVB induced wrinkle formation in vitro and in vivo. Biofactors 32:237–243CrossRefGoogle Scholar
  38. 38.
    Sanoobar M, Eghtesadi S, Azimi A, Khalili M, Khodadadi B, Jazayeri S, Gohari MR, Aryaeian N (2014) Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial. Nutr Neurosci 18:169–176CrossRefGoogle Scholar
  39. 39.
    Sachdanandam P (2008) Antiangiogenic and hypolipidemic activity of coenzyme Q10 supplementation to breast cancer patients undergoing tamoxifen therapy. Biofactors 32:151–159CrossRefGoogle Scholar
  40. 40.
    Burrage PS, Mix KS, Brinckerhoff CE (2006) Matrix metalloproteinases: role in arthritis. Front Biosci 11:529–543CrossRefGoogle Scholar
  41. 41.
    Nelson KK, Melendez JA (2004) Mitochondrial redox control of matrix metalloproteinases. Free Radic Biol Med 37:768–784CrossRefGoogle Scholar
  42. 42.
    Alge-Priglinger CS, Kreutzer T, Obholzer K, Wolf A, Mempel M, Kernt M, Kampik A, Priglinger SG (2009) Oxidative stress-mediated induction of MMP-1 and MMP-3 in human RPE cells. Invest Ophthalmol Vis Sci 50:5495–5503CrossRefGoogle Scholar
  43. 43.
    Vugt VRM, Rijken PJ, Rietveld AG, Van Vugt AC, Dijkmans BA (2008) Antioxidant intervention in rheumatoid arthritis: results of an open pilot study. Clin Rheumatol 27:771–775CrossRefGoogle Scholar
  44. 44.
    Sandoo A, Veldhuijzen van Zanten JJ, Metsios GS, Carroll D, Kitas GD (2011) Vascular function and morphology in rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 50:2125–2139CrossRefGoogle Scholar
  45. 45.
    Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D (2008) Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 59:1690–1697CrossRefGoogle Scholar
  46. 46.
    Meune C, Touzé E, Trinquart L, Allanore Y (2009) Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 48:1309–1313CrossRefGoogle Scholar
  47. 47.
    Kocaba H, Kocaba V, Büyükba S, Salli A, Ugurlu H (2010) Relationship of cellular oxidant and antioxidant status with disease activity in patients with rheumatoid arthritis. Turk J Rheumatol 25:141–146CrossRefGoogle Scholar
  48. 48.
    Shrivastava AK, Singh H, Raizada A, Singh S, Pandey A, Singh N, Yadav DS, Sharma H (2015) Inflammatory markers in patients with rheumatoid arthritis. Allergol Immunopathol 43:81–87CrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2019

Authors and Affiliations

  1. 1.Department of Nutritional Sciences, School of Nutritional Sciences and Food TechnologyKermanshah University of Medical SciencesKermanshahIran
  2. 2.Department of Community Nutrition, Faculty of NutritionTabriz University of Medical SciencesTabrizIran
  3. 3.Connective Tissue Diseases Research CenterTabriz University of Medical SciencesTabrizIran
  4. 4.Department of Rheumatology, Faculty of MedicineUrmia University of Medical SciencesUrmiaIran
  5. 5.Research Center for Environmental Determinants of Health (RCEDH), Health InstituteKermanshah University of Medical SciencesKermanshahIran
  6. 6.Department of Nutrition, Faculty of Nutritional Sciences and Food TechnologiesKermanshahIran

Personalised recommendations